Discovery >> Services >> ADME / Tox

Develop ADME-Tox profiles of your promising lead compounds

Sidebar Image
undefined undefined undefined 


Drug - Drug Interactions

Metabolite ID

spects undefined undefined

In Vivo DMPK

In Vitro Toxicity


Understanding the absorption, distribution, metabolism, excretion (ADME) and toxicity (Tox) properties of your compounds is critical in the drug discovery process and can be evaluated by a series of in vitro assays and in vivo studies.

There is a significant advantage to obtaining in vitro ADME data as early as possible in the drug discovery process. For example, hepatic metabolism is a primary determinant of pharmacokinetic behavior and rapid first-pass metabolism is a major cause of low bioavailability. In vitro ADME results serve as good indicators as to whether a compound will be bioavailable, thus these results can assist to eliminate problematic compounds early in discovery and be a useful guide for later stage studies.

Drug toxicity is often the major reason for the withdrawal of an approved drug from the market, with hepatic toxicity and cardiac toxicity being the top two most frequent reasons. While formal toxicity testing is traditionally completed during a late preclinical phase, it has become obvious that a failure at this stage results in significant setbacks and economic loss.

Our assays are designed with the intent to meet regulatory requirements and are suitable for evaluating ADME-Tox properties early in the drug discovery process. With Eurofins cost-effective ADME-Tox assays, we help our clients to eliminate failures earlier in the drug discovery process while liberating them from having to invest internal time and capital to conduct these studies themselves. 

ADME-Tox assays available from Eurofins:

  • In vivo PK
  • In vitro bioavailability/ADME
    • Solubility / Protein binding / Blood partitioning
    • Absorption
      • Permeability
      • P-gp substrate
    • Metabolism
      • Blood and plasma stability
      • Intrinsic clearance
      • CYP- and UGT-phenotyping
  • Drug-drug interactions
    • CYP inhibition and induction
    • UGT inhibition
    • transporter inhibition
  • Metabolite identification / Bioanalytical support
    • Metabolite identification
    • UGT and glutathione conjugates
    • Quantitative bioanalysis
  • In vitro Toxicity
    • Genotoxicity
      • In vitro micronucleus
      • Ames
    • Cardiotoxicity
      • hERG Channel Screening
      • CardiacProfiler™
      • Cardiotoxicity by human stem cell derived cardiomyoctes
    • Hepatotoxicity
    • Nephrotoxicity
    • Organtoxicity